HER2+ breast cancer treatment and cardiotoxicity: monitoring and management.

ABSTRACT:

Background

Breast cancer is a leading cause of death for women worldwide, with incidence increasing in lower-income countries. For patients with human epidermal growth factor receptor-2-positive (HER2+) breast cancer, widespread availability of several agents targeting the HER2 receptor has resulted in survival gains over the past decades. However, improved survival has resulted in an increased need for management and mitigation of adverse events associated with anticancer therapy. Cardiac adverse events such as decreased ejection fraction and heart failure have been of particular concern in patients with HER2+ breast cancer. Anti-HER2 agents and chemotherapies (specifically anthracyclines, which are frequently used to treat HER2+ disease) have been associated with cardiotoxicity.

SUBMITTER: Jerusalem G 

PROVIDER: S-EPMC6661020 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature